- Deep Learning Algorithms have the potential to unlock mechanisms of tissue regeneration for applications in age-related disease -
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 29, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that Co-CEO Dr. Michael D. West, will give a lecture at the Mensa Annual Gathering today titled, "Hayflick Rewound: Implications of Reversing the Aging of Human Cells." Dr. West will discuss the impact of aging on society, as well as fundamental advances in understanding its causes and strategies to intervene using regenerative medicine. Dr. West will describe an online Artificial Intelligence (AI) and Deep Learning (DL) resource called "Embryonic.AI" being launched this week by LifeMap Sciences, Inc., a BioTime subsidiary, for beta testing and designed to discover novel treatments that cause the body to scarlessly repair tissue damage, an emerging field called induced Tissue Regeneration (iTR).
The venue of Mensa 2016 was chosen in order to discuss the ongoing paradigm shift relating to the use of artificially-intelligent systems to surpass human performance in areas including image recognition, autonomous driving, and biomedical research. Dr. West's presentation along with a video describing AI-based discovery and iTR will be available on BioTime's website in the Events & Presentations section under Investors & Media.
Mensa, the high IQ society, provides a forum for intellectual exchange among its members in over 100 countries around the world.
Induced Tissue Regeneration
Humans and most mammals have only a limited capacity to repair tissues in the body resulting from trauma or degenerative disease. However, some animals, such as the Mexican salamander can profoundly regenerate injured tissues, even amputated limbs. Using pluripotent stem cells and its proprietary PureStem® technology, BioTime scientists have isolated > 200 diverse embryonic progenitor cell lines with the potential to regenerate tissue in humans similar to that occurring in naturally regenerating animals. Key to the uniqueness of BioTime's PureStem® technology is the observation that the cells produced using this proprietary method differ from adult-derived cells in that they still express molecules associated with early embryonic development when organs and tissues in the body are formed for the first time.
The transition from the ability to regenerate tissue in early embryonic development to the ability to merely produce scar tissue as adults is one of the most complex processes studied in biology today. BioTime in collaboration with Insilico Medicine is investigating the potential ability to apply machine intelligence to better understand the process. BioTime scientists believe that leading in this innovative application of AI and pluripotent stem cell technologies is key to the future of the industry. Additionally, broader applications of this system could include personalized regenerative pharmacology, cancer stem cell research, as well as advances in understanding and intervening in the aging process. This Computer-based DL program will be available online at http://discovery.lifemapsc.com and is called "Embryonic.AI." The discoveries made with Embryonic.AI have the potential to lead to the ability to induce scarless tissue regeneration in humans, an emerging field called iTR.
BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. The foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
In addition to the development of therapeutics, BioTime's research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.
About Insilico Medicine, Inc.
Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery and provides services to pharmaceutical companies. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8
BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160629005525/en/
Source: BioTime, Inc.
Dan L. Lawrence, 510-775-0510
EVC Group, Inc.
Michael Polyviou, 646-445-4800
Gotham Communications, LLC
Bill Douglass, 646-504-0890